Team McCallum

R&D for Lifetime of Life

Drug for diet, diabetes, HBP, cholesterol.

The International Congress on Obesity threw up one further story for a popular UK newspaper. Liraglutide cuts weight, controls blood sugar in diabetes, lowers blood pressure and raises ‘good’ cholesterol. The 4-in-1 diet jab.

Liraglutide has brand name Victoza and is already on the market as a diabetes treatment. It was approved in Europe for diabetes last year and in the US in January. So a number of readers were able to comment that, yes, they had lost a lot of weight while using it – for diabetes.

In a press release in June 2010, makers Novo Nordisk claimed data from the diabetes study showed it performed better on diabetes control and on weight reduction than rival Januvia (both in conjunction with diabetes drug metformin).

According to the UK newspaper “Liraglutide tricks the brain into thinking we are full despite eating 20 per cent less food.” It appears to produce about double the weight loss of orlistat (Xenical/Alli).

Liraglutide is not licenced for treatment of obesity. When trying to get approval for diabetes the US FDA raised safety questions, and the makers halted obesity halted obesity trials until they answered those queries.

The obesity trial restarted once US approval as a diabetes drug was gained. The trial is scheduled to end in 2013, which probably means 2014 as the earliest market date.


July 18, 2010 - Posted by | Cholesterol, Diabetes, High blood pressure, Januvia, Liraglutide - Victoza, News, Obesity, Orlistat, Success, Weight management

No comments yet.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: